Health-related quality of life in the NETTER-1 trial of 177Lu-Dotatate
In people with a slow-growing gut cancer, the radioactive treatment lutetium-177 dotatate did not just shrink tumours for longer - it also kept their day-to-day quality of life, including energy, pain and diarrhoea, better for much longer than the older drug it was compared with.
Overview
This is the health-related quality-of-life (HRQoL) analysis of NETTER-1, the phase 3 trial that established 177Lu-Dotatate (Lutathera) for progressive midgut neuroendocrine tumours. Patients (117 on 177Lu-Dotatate, 114 on high-dose octreotide) completed the EORTC QLQ-C30 and GI.NET-21 questionnaires at baseline and every 12 weeks. Time to deterioration (TTD), defined as a fall of 10 points or more from baseline in a domain, was compared between arms by intention to treat.
TTD was significantly longer with 177Lu-Dotatate across every domain tested: global health status (HR 0.406), physical functioning (HR 0.518), role functioning (HR 0.580), fatigue (HR 0.621), pain (HR 0.566), diarrhoea (HR 0.473), disease-related worries (HR 0.572) and body image (HR 0.425). The difference in median TTD was large in absolute terms - 28.8 months versus 6.1 months for global health status, and 25.2 versus 11.5 months for physical functioning.
Because NETTER-1's primary endpoint (progression-free survival) had already shown a large benefit, this paper mattered for showing the benefit was not bought at the cost of how patients felt day to day - in every domain measured, 177Lu-Dotatate patients did the same or better than those on high-dose octreotide, never worse. It is frequently cited alongside the primary NETTER-1 report to support PRRT's tolerability case to patients and payers.
- Time to QoL deterioration (10-point fall) was significantly longer with 177Lu-Dotatate than high-dose octreotide across all measured domains.
- Global health status: median TTD 28.8 months (177Lu-Dotatate) vs 6.1 months (octreotide); HR 0.406, p<0.001.
- Physical functioning: median TTD 25.2 vs 11.5 months; HR 0.518.
- Diarrhoea (HR 0.473), fatigue (HR 0.621) and pain (HR 0.566) all deteriorated significantly later on 177Lu-Dotatate.
People treated with the radioactive drug lutetium-177 dotatate kept feeling well for much longer - years rather than months, in several measures - than people on the standard high-dose hormone injection, on top of the tumour-control benefit already shown.
- Quality-of-life data are patient-reported and unblinded (the trial was open-label), which can bias favourable results toward the novel treatment.
- Questionnaires were completed only until disease progression, so long-term quality of life beyond that point is not captured here.
- This is a secondary/exploratory endpoint analysis of NETTER-1, not an independently powered trial.
Similar pages
not linked directly; found by shared links- Key paperResults and adverse events of personalised peptide receptor radionuclide therapy in 1048 patients with neuroendocrine neoplasms
Shares NETTER-1: 177Lu-Dotatate for midgut neuroendocrine tumours progressing on octreotide, Richard P. Baum, Peptide receptor radionuclide therapy (PRRT), Lutetium-177 dotatate and the tags neuroendocrine tumours, PRRT.
- PersonErik S. Mittra
Shares NETTER-1, Peptide receptor radionuclide therapy (PRRT), Lutetium-177 dotatate, Lutetium-177 and the tag PRRT.
- PairingPRRT (177Lu-DOTATATE) with capecitabine and temozolomide (CAPTEM)
Shares Jonathan R. Strosberg, Peptide receptor radionuclide therapy (PRRT), Lutetium-177 dotatate, Lutetium-177 and the tag neuroendocrine tumours.
- PersonLisa Bodei
Shares NETTER-1, Peptide receptor radionuclide therapy (PRRT), Lutetium-177 dotatate, Lutetium-177 and the tag PRRT.
- Pairing68Ga-DOTATATE PET before Lutathera (177Lu-DOTATATE)
Shares Richard P. Baum, Peptide receptor radionuclide therapy (PRRT), Lutetium-177 dotatate, Lutetium-177 and the tag neuroendocrine tumours.
- AgentLutetium-177 dotatate (radioligand equivalent)
Shares Small intestinal neuroendocrine tumours, Peptide receptor radionuclide therapy (PRRT), Lutetium-177 dotatate, Lutetium-177 and the tag neuroendocrine tumours.
- CompanyMolecular Targeting Technologies
Shares Small intestinal neuroendocrine tumours, Peptide receptor radionuclide therapy (PRRT), Lutetium-177 dotatate, Lutetium-177 and the tag PRRT.
- TrialCOMPETE
Shares Jonathan R. Strosberg, Small intestinal neuroendocrine tumours, Peptide receptor radionuclide therapy (PRRT), Lutetium-177.